4943-103 US

The undersided certifies that this communication is being deposited with the United States Postal Service as prepaid first class mail in an envelope addressed to Commissioner of Patents and Trademarks, P.O. Box 1450, Alexandria, VA 22313-1450 on August 18, 2004.

Diane Dunn McKay

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bourassa, et al.

Customer No.: 26817

Serial No.: 10/796,936

Group Art Unit: 1614

Filed: March 10, 2004

Examiner: TBD

Confirmation No.: 3284

Title: Method and Compound To Reduce The Incidence Of Diabetes In A Subject With

Chronic Heart Failure

Supplemental Information Disclosure Statement

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, Applicant hereby brings to the attention of the United States Patent and Trademark Office the following documents of which Applicant has been made aware. The documents are listed on the attached PTO Form 1449. Copies of the documents are enclosed.

Pursuant to the OG Notice of August 5, 2003 for U.S. national applications filed after June 30, 2003, the requirement for submitting a copy of each cited U.S. patent and each cited U.S. patent application publication as this requirement is waived, copies of the U.S. patent and U.S. patent application publications are not submitted.

Applicant submits that this Supplemental Information Disclosure Statement is submitted within six months of the filing date.

It is requested that the references be considered by the Examiner and be made of record as part of the available prior art under 37 C.F.R. § 1.104. It is believed that no fee is required. The Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 13-2165.

Respectfully submitted,

Diane Dunn McKay

Reg. No. 34,586

Attorney for Applicant

Date: 8 / 18 / 04

MATHEWS, COLLINS, SHEPHERD & McKAY 100 Thanet Circle, Suite 306 Princeton, NJ 08540 (609) 924-8555 - Telephone (609) 924-3036 - Facsimile

					Docket Number (Optional) 4943-103 US		Application Number			
INFORMATION DISCLOSURE ETATION (Use several sheets)					Applicant(s)		10/796,936			
		(Use several sheets/if necessar	n) (is)	Bourassa, et al. Filing Date						
MIR 2 0 2004 (2)					March 10, 2004	1614				
U.S. PATENT DOCUMENTS										
*EXAMINER INITIAL	I REF I DOCUMENT NUMBER TO THE I			NAME	CLASS	SUBCLASS		FILING DATE IF APPROPRIATE		
		M**						IFALLIS	FRIALE	
	 			<u> </u>						
	<u> </u>			<u> </u>						
	<u> </u>	<u> </u>	-10 - 100							
U.S. PATENT APPLICATION PUBLICATIONS *EXAMINER										
INITIAL	DEC DOCUMENT NUMBER		DATE	ļ	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
									-	
FOREIGN PATENT DOCUMENTS										
	REF	DOCUMENT NUMBER	DATE	COUNTRY CLASS			SUBCLASS	Trans YES	slation NO	
	WO 01/15673 A2 WO 03/032963 A2		03/08/2001	WIPO	WIPO			I ES	NO	
			04/24/2003	WIPO						
	1		OTHER I	OCUMEN'	TS (Including Author,	Title, Date, I	Pertinent Pages, Et	(c.)		
	Emmanuelle Vermes, et al.; Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure; 2003;									
	Circulation; 107 (9): 1291									
	L. Ryden, et al.; Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus; European Heart Journal; 2000; Vol. 21; 1967-1978									
EXAMINE	, D			DATE CONSIDERED						
					DATE CONSIDERED				ė ė	
		ial if citation considered, whether on nclude copy of this form with next o			ice with MPEP Section 609; Dr	raw line thro	ugh citation if not	in conform	ance and	